Irisin immunohistochemistry in gastrointestinal system cancers

Aydın, Süleyman; Kuloğlu, Tuncay; Ozercan,; Albayrak, Serdal; Bakal, Ünal; Yılmaz, Mustafa; Kalaycı, Mehmet; Yardım, Meltem; Saraç, Mehmet; Kazez, Ahmet; Koçdor, Hilal; Kanat, Burhan Hakan; Ozercan, I H; Gönen, Murat; Bilgen, Mehmet; Balgetir, Ferhat

doi:10.3109/10520295.2015.1136988

Cited by 76 publications

(69 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All these findings together with our present results suggest that irisin might be a new diagnostic indicator of the presence of cancer. However, in disagreement with these results, studies performed by Aydin et al (2016) revealed a significant increased irisin immunoreactivity in colon adenocarcinoma tissue compared with that in normal colon tissues in Turkish people. In vitro studies performed by Moon and Mantzoros (2014) showed that irisin at both physiological and pharmacological concentrations has no effects on cell proliferation, cell adhesion, and/or colony formation in HT29 and MCA38 colon cancer cell lines.…”

Section: Discussionmentioning

confidence: 79%

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

et al. 2018

View full text Add to dashboard Cite

Objectives: To explore the activating transcription factor 3 (ATF3) and fibronectin type III domain-containing protein 5 (FNDC5)/irisin protein levels in serum and mRNA levels in subcutaneous and visceral white adipose tissue (sWAT and vWAT) in normal-weight (NW) and overweight/obese (OW/OB) patients with colorectal cancer (CRC).Methods: 76 CRC patients and 40 healthy controls were recruited. Serum ATF3 and irisin levels were detected by using ELISA kits, and the mRNA expression levels in sWAT and vWAT were measured by performing RT-qPCR.Results: The serum ATF3 levels were greater by 37.2%, whereas the irisin levels were lower by 23.3% in NW+CRC patients compared with those in healthy controls. CRC was independently associated with both ATF3 and irisin levels. The probability of CRC greater by 22.3-fold in individuals with high ATF3 levels compared with those with low ATF3 levels, whereas the risk of CRC in subjects with high irisin levels was lower by 78.0% compared to the risk in those with low irisin levels after adjustment for age, gender, BMI, and other biochemical parameters. Serum ATF3 and irisin could differentiate CRC patients from controls with receiver operating characteristic (ROC) curve areas of 0.745 (95% CI, 0.655–0.823) and 0.656 (95% CI, 0.561–0.743), respectively. The combination of ATF3 and irisin exhibited improved diagnosis value accuracy with ROC curve areas of 0.796 (95% CI, 0.710–0.866) as well as 72.6% sensitivity and 80.0% specificity.Conclusion: Increased ATF3 and reduced irisin levels were observed in sera from CRC patients. Individuals with high ATF3 and low irisin levels were more likely to have CRC. ATF3 and irisin represent potential diagnostic biomarkers for CRC patients.

show abstract

Section: Discussionmentioning

confidence: 79%

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…However, the sample size in that study was too small and they did not compare FNDC5/irisin expression between HCC tissues and adjacent noncancer tissues. Using irisin immunohistochemistry, Aydin et al has showed that irisin expression was significantly increased in various gastrointestinal cancers, but not in HCC [6]. Irisin inhibits gluconeogenesis [13] and the liver plays key roles in the regulation of glucose production [14].…”

Section: Discussionmentioning

confidence: 99%

“…In cultured breast cancer cells, irisin reduced cell proliferation, viability, and migration and enhanced the cytotoxic effect of doxorubicin [4]. However, in HCC, one study showed that irisin expression was upregulated in HCC tissues [5], while another study did not [6]. These contradictory results indicate the complexity of the irisin expression/regulation in HCC.…”

Section: Introductionmentioning

confidence: 99%

Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma

Jia

Ren

et al. 2019

Disease Markers

View full text Add to dashboard Cite

Background. Hepatectomy remains one of the most effective treatments for patients with hepatocellular carcinoma (HCC); however, it can lead to serious complications. Irisin, a key regulator of energy metabolism, is secreted into the circulation by shedding of the extracellular portion of the fibronectin type III domain-containing 5 (FNDC5). We have shown that irisin administration alleviates liver ischemia-reperfusion injury in mice. However, the role of preoperative irisin levels in HCC patients who underwent hepatectomy remained unknown. The purpose of this study was to determine how irisin expression changes in HCC and to explore the relationship between preoperative serum irisin levels and complications after hepatectomy. Methods. FNDC5/irisin expression data in HCC were extracted from The Cancer Genome Atlas (TCGA) dataset. A total of 219 participants, including 102 healthy controls and 117 HCC patients, were recruited in this study. All HCC patients underwent hepatectomy at the First Affiliated Hospital of the Xi’an Jiaotong University. Preoperative serum irisin levels were measured by ELISA. Postoperative complications were assessed using the comprehensive complication index (CCI) score. The Pearson rank correlation coefficient was computed to assess the correlation between preoperative serum irisin levels and postoperative CCI scores. Results. In TCGA dataset, FNDC5/irisin expression was downregulated in HCC tissues (P<0.001). Similarly, serum irisin levels were decreased in HCC patients (P<0.001). Low preoperative serum irisin levels were significantly correlated with high CCI scores after hepatectomy. Conclusions. Irisin may be a novel serum biomarker in the diagnosis of HCC and a predictor of complications after hepatectomy.

show abstract

“…It is synthesized in many tissues including skeletal muscle and fat cells, and participates in the regulation of lipid and glucose metabolism (Aydin, 2014). Since irisin regulates fat metabolism, it plays an important role in the emergence and development of obesity, insulin resistance associated with obesity, diabetes, non-alcoholic fatty liver disease and other metabolic diseases (Aydin et al, 2016;Zhu et al, 2018). By increasing levels of uncoupling protein-1 (UCP1), Irisin converts white adipose tissue cells into brown adipose tissue cells and reduces obesity (Boström et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study

Aslan

Hakan

Eryılmaz

et al. 2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Aim: There is much evidence of an association between cancer and irisin that is an adipokine. This study researched on the relationship between prostate cancer (PCa) and irisin levels, and whether irisin can be used as a biomarker in the diagnosis of PCa. Materials and Methods: For the study groups, 50 primary PCa patients and 30 healthy male subjects were included in the PCa and healthy control groups, respectively. All volunteers in the healthy control group were screened for prostate cancer and other malignancies and chronic diseases. Volunteers who were determine to be completely healthy were included for healthy control group. In the serum samples of the subjects were measured free PSA, total PSA and irisin levels. Irisin levels were compared separately in terms of the Gleason scores and T stage. In addition to intergroup comparisons, the ROC curve for the irisin was plotted and power analysis was performed. Results: Free and total PSA levels in the PCa group were significantly higher compared to the healthy control group (p<0.05). In addition, irisin levels in the PCa group were significantly lower than in the healthy control group (p<0.05). There was no significant difference between irisin levels in the groups classified in terms of Gleason scores (p>0.05). When the cutoff value was taken as 8.1, the sensitivity and specificity of irisin for PCa were as 80.5% and 90%, respectively. Conclusion: The results of this study indicate that the levels of irisin in the PCa group are considerably reduced and irisin may be used as a biomarker as well as free and total PSA.

show abstract

Irisin immunohistochemistry in gastrointestinal system cancers

Cited by 76 publications

References 35 publications

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

Serum and Adipose Tissue mRNA Levels of ATF3 and FNDC5/Irisin in Colorectal Cancer Patients With or Without Obesity

Serum Irisin Predicts Posthepatectomy Complications in Patients with Hepatocellular Carcinoma

Can the Irisin be a Biomarker for Prostate Cancer? A Case Control Study

Contact Info

Product

Resources

About